

In the claims:

For the convenience of the Examiner, all claims being examined, whether or not amended, are presented below.

1. **(Previously presented)** A transgenic mouse comprising a genome comprising a) exactly one functional elastin gene and b) either one mouse elastin gene comprising a null mutation or no second elastin gene, wherein said mouse has an increased number of elastin lamellae.
2. **(Previously presented)** A transgenic mouse comprising a genome with no functional elastin gene, wherein said mouse has arterial occlusion.
3. **(Currently amended)** An isolated mouse cell derived from the transgenic mouse of claim 1 ~~comprising a genome comprising a) exactly one functional elastin gene and b) one mouse elastin gene comprising a null mutation or no second elastin gene.~~
4. **(Currently amended)** An isolated mouse cell derived from the transgenic mouse of claim 2, wherein said cell comprises ~~comprising~~ i) a genome with no elastin gene or ii) a genome with a) elastin gene comprising a null mutation and b) no functional elastin gene.
5. **(Currently amended)** A method to screen for drug candidates that may be useful for treating humans with supraaortic stenosis (SVAS), hypertension or atherosclerosis or useful for preventing atherosclerosis in humans, said method comprising administering said drugs to the mouse of claim 1 or 2 or contacting the cells of claim 3 or 4 ~~an *ELN*^{+/-} mouse or *ELN*^{+/-} human, wherein said *ELN*^{+/-} mouse or said *ELN*^{+/-} human comprises a genome with a) exactly one functional elastin gene and b) either one elastin gene comprising a null mutation or no second elastin gene, wherein said *ELN*^{+/-} mouse or said *ELN*^{+/-} human has an increased number of elastic lamellae, wherein drugs which can inhibit occlusion of arteries in said mouse or inhibit proliferation in said cells *ELN*^{+/-} mouse or said *ELN*^{+/-} human are said drug candidates.~~

6-8. **(Cancelled)**

9. **(Currently amended)** A method to screen for a drug candidate that may be useful for treating atherosclerosis, hypertension or supra-ventricular aortic stenosis (SVAS) in a human, said method comprising treating the mouse of claim 1 or 2 or contacting the cells of claim 3 or 4 an ~~*ELN* +/- mouse, *ELN* +/- human, *ELN* +/- mouse cells or *ELN* +/- human cells, wherein said *ELN* +/- mouse, *ELN* +/- human, *ELN* +/- mouse cells or *ELN* +/- human cells comprise a genome with a) exactly one functional elastin gene and b) either one elastin gene comprising a null mutation or no second elastin gene, wherein said *ELN* +/- mouse or said *ELN* +/- human has an increased number of elastic lamellae,~~ with drugs and measuring synthesis of elastin RNA, wherein a drug which increases synthesis of elastin RNA in said ~~*ELN* +/- mouse, said *ELN* +/- human, said *ELN* +/- mouse cells or said *ELN* +/- human~~ mouse or cells is said drug candidate.

10. **(Currently amended)** A method to screen for a drug candidate that may be useful for treating atherosclerosis, hypertension or supra-ventricular aortic stenosis (SVAS) in a human, said method comprising treating the mouse of claim 1 or 2 or contacting the cells of claim 3 or 4 ~~*ELN* +/- mice or *ELN* +/- mouse cells, wherein said *ELN* +/- mice or *ELN* +/- mouse cells comprise a genome with a) exactly one functional elastin gene and b) either one elastin gene comprising a null mutation or no second elastin gene, wherein said mouse has an increased number of elastin lamellae,~~ with drugs and measuring synthesis of elastin, wherein a drug which increases synthesis of elastin is said drug candidate.

11-14. **(Cancelled)**

◇◇ Please enter the following new claims:

15. **(NEW)** Tissue isolated from the transgenic mouse of claim 1 or 2.